ATE165918T1 - Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper - Google Patents

Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper

Info

Publication number: ATE165918T1
Authority: AT; Austria
Prior art keywords: dms; antibodies; mammals; components; cerebral amyloid
Prior art date: 1993-12-17

Application number

AT95903728T

Other languages

English (en)

Inventor

Paul Averback

Original Assignee

Nymox Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-17

Filing date

1994-12-19

Publication date

1998-05-15

1994-12-19 Application filed by Nymox Corp filed Critical Nymox Corp

1998-05-15 Application granted granted Critical

1998-05-15 Publication of ATE165918T1 publication Critical patent/ATE165918T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/839—Nerves; brain

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT95903728T 1993-12-17 1994-12-19 Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper ATE165918T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/168,250 US5525339A (en)	1986-08-27	1993-12-17	Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto

Publications (1)

Publication Number	Publication Date
ATE165918T1 true ATE165918T1 (de)	1998-05-15

Family

ID=22610731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95903728T ATE165918T1 (de)	1993-12-17	1994-12-19	Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper

Country Status (10)

Country	Link
US (4)	US5525339A (de)
EP (1)	EP0733214B1 (de)
JP (1)	JPH09507748A (de)
AT (1)	ATE165918T1 (de)
AU (1)	AU702153B2 (de)
CA (1)	CA2175451C (de)
DE (1)	DE69410116T2 (de)
DK (1)	DK0733214T3 (de)
ES (1)	ES2118545T3 (de)
WO (1)	WO1995016917A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5525339A (en) *	1986-08-27	1996-06-11	Dms Pharmaceutical Inc.	Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5231170A (en) *	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
US6413940B1 (en) *	1997-02-07	2002-07-02	Nymox Corporation	Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US7514407B2 (en) *	2002-03-04	2009-04-07	Nymox Corporation	Spheron component peptides and pharmaceutical compositions
DE60311433D1 (de) *	2002-03-04	2007-03-15	Nymox Corp	Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle
AU2003279216A1 (en) *	2002-10-09	2004-05-04	Rinat Neuroscience Corp.	Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2005290250A1 (en) *	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
MY148086A (en) *	2005-04-29	2013-02-28	Rinat Neuroscience Corp	Antibodies directed against amyloid-beta peptide and methods using same
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
PL1976877T5 (pl)	2005-11-30	2017-09-29	Abbvie Inc	Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
WO2007068412A2 (en)	2005-12-12	2007-06-21	Ac Immune Sa	A beta 1-42 specific monoclonal antibodies with therapeutic properties
US7892544B2 (en)	2006-07-14	2011-02-22	Ac Immune Sa	Humanized anti-beta-amyloid antibody
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en)	2007-02-27	2010-12-09	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
WO2009048539A2 (en)	2007-10-05	2009-04-16	Genentech, Inc.	Monoclonal antibody
MX336196B (es)	2010-04-15	2016-01-11	Abbvie Inc	Proteinas de union a amiloide beta.
US9221900B2 (en)	2010-07-30	2015-12-29	Ac Immune S.A.	Methods for identifying safe and functional humanized antibodies
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4919915A (en) *	1987-03-03	1990-04-24	Paul Averback	Method for detecting the ability to prevent red-to-green congophilic birefringence
US5231170A (en) *	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
US6727278B1 (en) *	1986-08-27	2004-04-27	Dms Pharmaceutical Inc.	Pharmaceutically active agents that impede amyloid formation in vivo
US4816416A (en) *	1986-08-27	1989-03-28	Paul Averback	Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions
US5525339A (en) *	1986-08-27	1996-06-11	Dms Pharmaceutical Inc.	Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5262332A (en) *	1989-04-05	1993-11-16	Brigham And Women's Hospital	Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) *	1989-06-01	1993-08-10	Du Pont Merck Pharmaceutical Company	Diagnostic assay for alzheimer's disease
US5100645A (en) *	1990-10-19	1992-03-31	Royal Institution For The Advancement Of Learning (Mcgill Univ.)	Method of diagnosis of amyloidosis
US5441870A (en) *	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) *	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6413940B1 (en) *	1997-02-07	2002-07-02	Nymox Corporation	Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US6130221A (en) *	1997-03-05	2000-10-10	Nymox Corporation	Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
US6913745B1 (en) *	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease

1993
- 1993-12-17 US US08/168,250 patent/US5525339A/en not_active Expired - Fee Related
1994
- 1994-12-19 WO PCT/CA1994/000689 patent/WO1995016917A1/en active IP Right Grant
- 1994-12-19 JP JP7516431A patent/JPH09507748A/ja active Pending
- 1994-12-19 DK DK95903728T patent/DK0733214T3/da active
- 1994-12-19 DE DE69410116T patent/DE69410116T2/de not_active Expired - Fee Related
- 1994-12-19 AT AT95903728T patent/ATE165918T1/de not_active IP Right Cessation
- 1994-12-19 ES ES95903728T patent/ES2118545T3/es not_active Expired - Lifetime
- 1994-12-19 EP EP95903728A patent/EP0733214B1/de not_active Expired - Lifetime
- 1994-12-19 AU AU12695/95A patent/AU702153B2/en not_active Ceased
- 1994-12-19 CA CA002175451A patent/CA2175451C/en not_active Expired - Fee Related
1996
- 1996-06-10 US US08/660,886 patent/US6309892B1/en not_active Expired - Fee Related
2001
- 2001-10-29 US US09/984,304 patent/US20020028473A1/en not_active Abandoned
2004
- 2004-12-29 US US11/024,223 patent/US20050191711A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK0733214T3 (da)	1999-03-15
ES2118545T3 (es)	1998-09-16
US20050191711A1 (en)	2005-09-01
US5525339A (en)	1996-06-11
EP0733214B1 (de)	1998-05-06
WO1995016917A1 (en)	1995-06-22
AU1269595A (en)	1995-07-03
DE69410116T2 (de)	1998-12-17
JPH09507748A (ja)	1997-08-12
EP0733214A1 (de)	1996-09-25
CA2175451A1 (en)	1995-06-22
CA2175451C (en)	2000-10-31
US20020028473A1 (en)	2002-03-07
DE69410116D1 (de)	1998-06-10
AU702153B2 (en)	1999-02-18
US6309892B1 (en)	2001-10-30

Publication	Publication Date	Title
ATE165918T1 (de)	1998-05-15	Aus bestandteilen im gehirngewebe der säugetiere ableitbare dichte mikrokugeln und dagegen gerichtete antikörper
EP0792156A4 (de)	2000-03-01	Verfahren zur vorbeugung oder behandlung von vaskulären hämorragien und der alzheimerischen krankheit
BR0016652A (pt)	2002-11-19	Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
US5443960B1 (en)	1999-01-12	Method for the diagnosis of blood coagulation disorders
EP0686203A4 (de)	1999-08-25	Verbindungen und methoden zur diagnose, behandlung und vorbeugung von durch den zelltod bedingten krankheiten
EP0536335A4 (en)	1993-07-14	Compositions and methods for the prevention and diagnosis of lyme disease
CA2245661A1 (en)	1997-08-21	Multiple sclerosis treatment
EP1445317A3 (de)	2004-12-15	Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs
EP0727985A4 (de)	1997-07-02	Präparat und verfahren zur behandlung von blutgefässerkrankungen der haut unter verwendung von vitamin k
NO20100264L (no)	2002-01-25	Forhindring og behandling av amyloidogen sykdom
CA2164291A1 (en)	1994-12-22	Methods and pharmaceutical compositions useful for treating neurological disorders
WO1995024650A3 (en)	1995-10-05	Methods of diagnosing and treating preeclampsia
WO2002016581A3 (en)	2003-01-16	Compositions and methods for the diagnosis and treatment of tumor
AU5309600A (en)	2000-12-18	Compositions and methods for the treatment and diagnosis of immune disorders
WO2002016602A3 (en)	2003-02-06	Compositions and methods for the diagnosis and treatment of tumor
WO1999048489A3 (en)	1999-12-02	Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
PL367089A1 (en)	2005-02-21	Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
DE69124380D1 (de)	1997-03-06	Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
WO2002062205A3 (en)	2003-09-12	Methods for diagnosing and treating heart disease
WO2003001877A3 (en)	2003-09-12	Methods for the diagnosis and treatment of cardiac tissue rejection
WO2001042205A3 (en)	2002-03-21	Treatment of inflammatory bowel disease with vitamin d compounds
WO2003028536A3 (en)	2003-11-13	Methods for diagnosing and treating heart disease
NO970109D0 (no)	1997-01-10	Kompleksforbindelser for diagnose av karsykdommer
ATE164230T1 (de)	1998-04-15	4verfahren und zusammensetzungen zur vorbeugung, diagnose und behandlung seröser entzündungen und damit verbundener störungen
DE3235347A1 (de)	1984-03-29	Stereo-geraeuschmagnetfeld-therapiegeraet

Legal Events

Date	Code	Title	Description
1999-01-15	UEP	Publication of translation of european patent specification
2007-09-15	REN	Ceased due to non-payment of the annual fee